Novel mechanism found that may boost impaired function of leukemia protein

A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia. The protein, called AML1, plays a critical role in the development of the blood system and in the production of platelets and immune cells. The findings are published in the March 1, 2008, issue of Genes & Development.

According to the study, investigators identified the methyltransferase enzyme that controls the activity of the normal AML1 protein – also called RUNX1 – demonstrating its ability to regulate the function of transcription factors, proteins that control cell fate by turning genes on or off.

The researchers found that the cellular pathways that regulate the activity of the normal AML1 protein through a process called arginine methylation cannot similarly regulate the activity of AML1-ETO, a protein associated with causing acute leukemia.

Methylation is the process by which methyltransferases catalyze the attachment of a methyl group to DNA or protein in order to regulate gene expression or protein function. Demethylase enzymes that remove methyl groups from proteins have only recently been discovered.

“By manipulating the activity of these enzymes, it may be possible to promote the activity of the normal protein, and thereby lessen the impact of the protein that promotes leukemia,” said the study’s senior author Stephen D. Nimer, MD, Chief of the Hematology Service at MSKCC. “We are just beginning to explore whether we can tilt the balance toward a normally functioning AML1 protein in leukemic cells and either trigger their death or their reversion to normal behavior.”

There are currently no available drugs that target protein methylation, although two drugs that target DNA methylation are FDA approved for treating patients with myelodysplastic syndromes.

“We hope to utilize these new findings to help develop and ultimately test new treatment strategies for patients with either myeloid or lymphoid types of acute leukemia,” said the study’s first author, Xinyang Zhao, a member of Dr. Nimer’s laboratory.

Dr. Nimer has been researching the AML1-ETO protein at MSKCC since 1993. He and his colleagues first demonstrated in 1995 that AML1-ETO functions as a transcriptional repressor and dominantly inhibits AML1 function.

Source: Memorial Sloan-Kettering Cancer Center

Related stories:

Protein shown to play a key role in normal development of nervous system
A protein that enables nerve cells to communicate with each other plays a key role in controlling the developing nervous system. Research into how that protein helps precise connections to form among nerve cells may provide a basis for eventual treatments for patients who suffer injuries to their nervous system, including spinal cord injury.
Study provides insight on a common heart rhythm disorder
University of Iowa researchers and colleagues in France have identified a gene variant that causes a potentially fatal human heart rhythm disorder called sinus node disease. Also known as "sick sinus syndrome," the disease affects approximately one in 600 heart patients older than 65 and is responsible for 50 percent or more of the permanent pacemaker placements in the United States.
Food for thought -- regulating energy supply to the brain during fasting
If the current financial climate has taught us anything, it's that a system where over-borrowing goes unchecked eventually ends in disaster. It turns out this rule applies as much to our bodies as it does to economics. Instead of cash, our body deals in energy borrowed from muscle and given to the brain.
Form of Crohn's disease traced to disabled gut cells
Scientists report online this week in Nature that they have linked the health of specialized gut immune cells to a gene associated with Crohn's disease, an often debilitating and increasingly prevalent inflammatory bowel disorder.
Discovery of natural compounds that could slow blood vessel growth
Using computer models and live cell experiments, biomedical engineers at the Johns Hopkins University School of Medicine have discovered more than 100 human protein fragments that can slow or stop the growth of cells that make up new blood vessels.
Nutritionists show what beans are worth
Consider a natural alternative the next time you reach for that cupcake or soda as an afternoon snack. This snack leaves you feeling full, gives you energy, and simultaneously fights “bad”—LDL—cholesterol.
First glimpse of a key DNA repair protein at work
Repairing breaks in the two strands of the DNA double helix is critical for avoiding cancer. In humans and other organisms, a molecular machine called the MRN complex is responsible for finding and signaling double-strand breaks (DSBs), then launching the error-free method of DNA repair called homologous recombination.
Research team discovers brain pathway responsible for obesity
University of Wisconsin-Madison researchers, for the first time, have found a messaging system in the brain that directly affects food intake and body weight.

News discussion:

Medicine & Health news